Financials
Financial year 2025
XLENCE PHARMA from Braine-l'Alleud, company number BE0792642824, closed financial year 2025 with a result of € 7,032 after tax. For that financial year XLENCE PHARMA recorded a gross margin of € 13,891 and equity of € 64,754. Compared with financial year 2024, the result moved from € 19,923 to € 7,032. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 4, 2026.
€ 64,754
▲ 12% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7,032
▼ 65% vs 2024
Profit after tax over the fiscal year.
€ 44,580
▼ 10% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 59,754.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 1,383
▲ 67% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3,928
▲ 244% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 14,812
▼ 39% vs 2024
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 53,747 | € 34,571 | € 13,891 | ▼ 60% |
| Profit after taxes | € 32,799 | € 19,923 | € 7,032 | ▼ 65% |
| Equity | € 37,799 | € 57,722 | € 64,754 | ▲ 12% |
| Total debts | € 48,000 | € 25,440 | € 19,417 | ▼ 24% |
| Cash | € 49,031 | € 49,792 | € 44,580 | ▼ 10% |
| Retained profit | € 32,799 | € 52,722 | € 59,754 | ▲ 13% |
| Balance sheet total | € 85,799 | € 83,162 | € 84,171 | ▲ 1% |
Key figures of XLENCE PHARMA, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to XLENCE PHARMA?
What happened at XLENCE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 7,032 (▼ 65% vs 2024). Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Braine-l'Alleud. KBO
- Morgane VAN DE STADT became a director. NBB
In short
From € 32,799 profit in 2023 to € 7,032 profit in 2025.
Paid € 19,702 in corporate taxes since 2023.
Best year ever: 2023, with € 32,799 profit.
Management
Behind XLENCE PHARMA is Morgane VAN DE STADT.
Directors
According to the 2025 annual accounts
Morgane VAN DE STADT
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Rue du Try 43
1421 Braine-l'Alleud
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- VAN DE STADT Morgane Pierre Elisabeth(oprichter) 100%
Details
- Company number
- 0792.642.824
- VAT number
- BE 0792.642.824
- Registered office
- Rue du Try 43, 1421 Braine-l'Alleud
- Names & denominations
- XLENCE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 October 2022
- Peppol
- Active · Active since 25 Oct 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering